2016 - IHE

Persson U, Steen Carlsson K and Jönsson B Alternative Payment Models in Haemophilia Treatment Lund: IHE Report 2016:10
Hjalte F, Ragnarson Tennvall G, Welin K-O and Westerling D Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden Pain and Therapy, 2016; 5(2): 227-236
DOI: 10.1007/s40122-016-0059-9
Lundqvist A, Andersson E and Steen Carlsson K The costs of diabetes in 2020 and 2030 − A model analysis comparing innovative glucose lowering treatments in second line following European and American guidelines compared to current standard of care IHE Report 2016:9, IHE: Lund
Liedberg F, Gerdtham U, Gralén K, Gudjonsson S, Jahnson S, Johansson I, Hagberg O, Larsson S, Lind AK, Löfgren A, Wanegård J, Åberg H and Nilbert M Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective: results from a prospective intervention study British Journal of Cancer. 2016 Sep 27; 115(7): 770-5
DOI: 10.1038/bjc.2016.265
Persson S, Gerdtham UG and Steen Carlsson K for the Swedish Childhood Diabetes Study Group Labor market consequences of childhood onset type 1 diabetes Economics and Human Biology 2016; 23: 180-192
DOI: 10.1016/j.ehb.2016.09.003
Öien RF, Forsell H and Ragnarson Tennvall G Cost consequences due to reduced ulcer healing times – analyses based on the Swedish Registry of Ulcer Treatment International Wound Journal 2016; 13(5): 957-962
DOI: 10.1111/iwj.12465
Cole A, Lundqvist A, Lorgelly P, Norrlid H, Karlsberg Schaffer S, Lewis F, Hernandez-Villafuerte K, Lindgren P, Garau M, Welin K-O, Bianchi S, Althin R, O’Neill P, Persson U, and Towse A Improving Efficiency and Resource Allocation in Future Cancer Care London, UK: Consulting Report OHE-IHE, September 2016
Jönsson B, Hofmarcher T, Lindgren P & Wilking N The cost and burden of cancer in the European Union 1995-2014 Eur J Cancer. 2016 Aug 30; 66: 162-170
DOI: 10.1016/j.ejca.2016.06.022
Lanbeck P, Ragnarson Tennvall G & Resman F A cost analysis of introducing an infectious disease specialist-guided antimicrobial stewardship in an area with relatively low prevalence of antimicrobial resistance BMC Health Services Research (2016) 16: 311
DOI: 10.1186/s12913-016-1565-5
Olofsson S, Norrlid H, Karlsson E, Wilking U & Ragnarson Tennvall G Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting The Breast 2016; 29: 140-146
DOI: 10.1016/j.breast.2016.07.008